Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
Earnings Data
Report Date
Oct 30, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-1.57Last Year’s EPS
-1.36Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call reflected significant progress in regulatory milestones, commercial readiness, and positive clinical trial outcomes, particularly for aficamten. However, increased expenses and net losses, along with the extended PDUFA date, present challenges. The call balanced optimism about upcoming approvals and commercial launches with caution about financial and regulatory hurdles.Company Guidance -
Q3 2025
Progress in Regulatory Milestones
The FDA extended the PDUFA date for aficamten to December 26, 2025. Regulatory reviews in Europe and China are ongoing, with potential approval in China expected in the second half of this year and in Europe by the first half of 2026.
Commercial Readiness for Aficamten
A strong and experienced U.S. sales force has been recruited with over 8,800 applications and nearly all territories filled. The commercial launch in the U.S. is planned for early Q1 2026.
Positive Clinical Trial Results
The MAPLE-HCM trial showed a statistically significant improvement in peak oxygen uptake for aficamten compared to the standard of care beta blocker, metoprolol. The pivotal Phase III trial in nHCM is fully enrolled ahead of schedule.
Financial Stability
The company ended the quarter with approximately $1.04 billion in cash, cash equivalents, and investments. Full-year 2025 financial guidance is being maintained.
CYTK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CYTK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 07, 2025 | $35.25 | $34.11 | -3.23% |
May 06, 2025 | $33.97 | $33.04 | -2.74% |
Feb 27, 2025 | $47.45 | $46.00 | -3.06% |
Nov 06, 2024 | $55.50 | $55.84 | +0.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cytokinetics (CYTK) report earnings?
Cytokinetics (CYTK) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).
What is Cytokinetics (CYTK) earnings time?
Cytokinetics (CYTK) earnings time is at Oct 30, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CYTK EPS forecast?
CYTK EPS forecast for the fiscal quarter 2025 (Q3) is -1.57.